Expert Interviews

STEP 1 and STEP 3 Results with Thomas Wadden, PhD

March 02, 2021

Published in late February, results of the STEP 1 and STEP 3 trial give clinicians insight into the effects of 2.4 mg subcutaneous semaglutide as an intervention for weight loss in overweight or obese patients ahead of a potential approval in June 2021.

Reflecting on World Diabetes Day 2020: The Nurse and Diabetes

November 14, 2020

In honor of World Diabetes Day, we reached out to Lucia Novak, CRNP, to get her perspective on the role of nurses in the diabetes care model as "The Nurse and Diabetes" has been chosen as the official theme of this year's World Diabetes Day.